Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs.

ABSTRACT: Drugs produce their therapeutic effects by modulating specific targets, and there are 89 innovative targets of first-in-class drugs approved in 2004-17, each with information about drug clinical trial dated back to 1984. Analysis of the clinical trial timelines of these targets may reveal the trial-speed differentiating features for facilitating target assessment. Here we present a comprehensive analysis of all these 89 targets, following the earlier studies for prospective prediction of clinical success of the targets of clinical trial drugs. Our analysis confirmed the literature-reported common druggability characteristics for clinical success of these innovative targets, exposed trial-speed differentiating features associated to the on-target and off-target collateral effects in humans

SUBMITTER: Li YH 

PROVIDER: S-EPMC7299286 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature